StemCyte International Unit OKs $5 Million Cash Capital Increase
StemCyte International (TPE:4178) said its major unit StemCyte approved a cash capital increase of $4.7 million to boost working capital.The new shares will carry the same rights as existing shares and will be fully subscribed by parent company StemCyte International, according to a Wednesday Taiwan Exchange filing.StemCyte International is a regenerative therapeutics and umbilical cord blood banking company in Taiwan.